Impact of anti-obesity medication initiation and duration on weight loss in a comprehensive weight loss programme

3Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective: This retrospective study aimed to evaluate the impact of anti-obesity medication (AOM) initiation, usage and duration on weight loss in a 72-week precision obesity programme. The type of AOM, diet and exercise plan was chosen based upon an individual's biological and psychosocial needs. The 72-week study duration allowed for a fair investigation of the downstream impact of delayed versus early AOM initiation. Methods: Participants, aged ≥18 years with body mass index ≥30 kg m−2, enrolled from 1 March 2015 to 1 April 2017, were included. Subgroups were assigned by AOM usage (users versus non-users, early [before 8 weeks] versus delayed [after 8 weeks] AOM initiation and short [<6 months] versus long [≥6 months] AOM duration). Primary endpoints included change in baseline weight at 72 weeks and proportions achieving ≥5%, ≥10% and ≥15% weight loss. Outcomes were compared between subgroups. Results: Mean age and body mass index (N = 129) were 45.0 ± 14.0 years and 37.0 ± 6.0 kg m−2, respectively; 67% were female. At week 72, AOM users (N = 71) achieved significantly greater mean percentage reduction in baseline weight than non-users (N = 58). On average, baseline weight decreased by 14.04 ± 6.2% in users versus 10.9 ± 6.8% in non-users (P = 0.008); 84% and 94% of non-user and AOM users lost >5% weight loss (P = 0.006). A higher proportion of users lost ≥15% of weight (45.1% vs. 19.0%; P < 0.001). Mean percentage reduction in weight was greater for early versus delayed starters (−17.60 ± 5.3% vs. −13.95 ± 5.5%; P = 0.024), and longer AOM usage trended towards increased weight loss. Conclusion: Early initiation of AOM may enhance weight loss.

References Powered by Scopus

A randomized, controlled trial of 3.0 mg of liraglutide in weight management

1760Citations
N/AReaders
Get full text

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society

1747Citations
N/AReaders
Get full text

Pharmacological management of obesity: An endocrine society clinical practice guideline

954Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Impact of a Community-Based Weight Management Program in a North Carolina Health Care System

5Citations
N/AReaders
Get full text

Comparison study between drugs (Orlistat and chitocal) and food supplements (green tea and apple cider vinegar) for weight loss and hepatoprotection in rats

4Citations
N/AReaders
Get full text

Clinical and Cost Benefits of Anti-Obesity Medication for US Veterans Participating in the MOVE! Weight Management Program

2Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Safavi, R., Lih, A., Kirkpatrick, S., Haller, S., & Bailony, M. R. (2019). Impact of anti-obesity medication initiation and duration on weight loss in a comprehensive weight loss programme. Obesity Science and Practice, 5(5), 468–478. https://doi.org/10.1002/osp4.361

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 7

78%

Professor / Associate Prof. 1

11%

Researcher 1

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 8

73%

Materials Science 1

9%

Pharmacology, Toxicology and Pharmaceut... 1

9%

Economics, Econometrics and Finance 1

9%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 6

Save time finding and organizing research with Mendeley

Sign up for free